| Date | Title | | | 12/05/06 | Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for Seasonal Allergic Rhinitis| DURHAM, N.C.--(BUSINESS WIRE)--Dec. 5, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of
a Phase 2 clinical trial to evaluate epinastine nasal spray for the
treatment of seasonal allergic rhinitis.
This Phase 2 clinical trial is a 14-day randomized, double-blind
comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to
placebo in approximately 580 subjects who have a documented history of
seasonal allergic rhinitis to mountain cedar p... |
|  | | 11/07/06 | Inspire Reports Third Quarter 2006 Financial Results| Third Quarter 2006 Revenue Increases 48% from Third Quarter 2005
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today reported financial results
for the third quarter ended September 30, 2006.
Total revenue for the third quarter of 2006 was $9.7 million,
which was generated from co-promotion activities, compared to $6.6
million for the third quarter of 2005. Co-promotion revenue from net
sales of Elestat(R) (epinastine HCl ophthalmic ... |
| | | 11/03/06 | Inspire Announces Progress in Cystic Fibrosis Program| - Results of Pediatric Phase 2 Safety Trial Presented at North
American Cystic Fibrosis Conference -
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today several updates
in its development program for denufosol tetrasodium for the treatment
of cystic fibrosis (CF).
A poster presentation entitled "Safety and Tolerability of
Denufosol Inhalation Solution: Results of a 28-Day Phase 2 Study in
5-7 Year Old Pati... |
| | | 11/01/06 | Inspire and FAES Farma Announce Licensing Agreement for New Oral Antihistamine to Target Allergy Market in United States and Canada|
Inspire Expands Allergy Product Portfolio with Phase 3 Compound
Pharmaceutical Writers/Business Editors
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) and FAES Farma, S.A. (IBEX: FAE)
announced today the signing of a licensing agreement for the U.S. and
Canadian development and commercialization of bilastine, a Phase 3
oral antihistamine compound for the treatment or prevention of
allergic rhinitis, a condition affecting approxima... |
| | | 10/30/06 | Inspire Names New Member to Board of Directors| Business Editors/Health/Medical Writers
DURHAM, N.C.--(BUSINESS WIRE)--Oct. 30, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced the election of
Nancy J. Hutson, Ph.D., to Inspire's Board of Directors, effective
October 27, 2006.
Dr. Hutson was elected by Inspire's Board of Directors to fill the
single vacancy on the Company's Board and will serve the remainder of
a three-year term that will expire at Inspire's 2009 annual meeting of
stockholders. Dr. Hutson... |
| | | 10/24/06 | Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Life Sciences Conference| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 24, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg,
Towbin Life Sciences Conference on Tuesday, October 31, 2006 at 8:00
am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited... |
| | | 10/24/06 | Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2006 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 24, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to
report third quarter 2006 financial results on Tuesday, November 7,
2006 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on November 7, 2006 at 10:00 a.m.
ET.
To access the conference call, U.S. participants may call (877)
780-2276 and int... |
| | | 10/23/06 | Inspire Receives Wells Notice from U.S. Securities and Exchange Commission Staff| DURHAM, N.C., Oct 23, 2006 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
it received a Wells Notice letter on October 19, 2006 from the staff
of the U.S. Securities and Exchange Commission (Commission), issued in
connection with a Commission investigation that the Company previously
disclosed relating to its Phase 3 clinical trial of the Company's dry
eye product candidate, Prolacria(TM). The Company's Chief Executive
Officer and its Executive Vice Pr... |
| | | 10/12/06 | Inspire Announces Webcast of Presentation at BIO InvestorForum 2006| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 12, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Benjamin R.
Yerxa, Ph.D., Inspire's Chief, Scientific Operations and Alliances,
will present at the BIO InvestorForum 2006 Conference on Thursday,
October 19, 2006 at 10:40 am PT (1:40 pm ET) in San Francisco.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be avail... |
| | | 10/10/06 | Inspire Begins Phase 2 Clinical Program of Epinastine for Seasonal Allergic Rhinitis| Business Editors/Health/Medical Writers
DURHAM, N.C.--(BUSINESS WIRE)--Oct. 10, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that an
investigational new drug application (IND) for epinastine nasal spray
has been filed with the U.S. Food and Drug Administration (FDA) and is
in effect, having passed the 30-day review period. Inspire previously
acquired certain exclusive rights from Boehringer Ingelheim to develop
and market an intranasal dosage form of epinasti... |
| | | 10/05/06 | Inspire Continues Discussions with FDA on Dry Eye Program| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 5, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) met with the U.S. Food and Drug
Administration (FDA) in late September 2006 to continue ongoing
discussions related to Inspire's dry eye clinical program for
Prolacria(TM) (the proposed U.S. trade name for diquafosol tetrasodium
ophthalmic solution 2%).
Based on this meeting, Inspire plans to provide the FDA with
additional information to facilitate ongoing discussions related to
Prolacria. ... |
| | | 09/19/06 | Inspire Announces Webcasts of Presentations at UBS and Noble Financial Conferences| DURHAM, N.C.--(BUSINESS WIRE)--Sept. 19, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that senior
executives from the Company will present at the UBS Global Life
Sciences Conference on Tuesday, September 26, 2006 at 1:30 p.m. ET in
New York City and the Noble Financial Small Cap Conference on
Thursday, September 28, 2006 at 9:45 a.m. ET in Charlotte, North
Carolina.
Both presentations will be webcast on Inspire's web site at
www.inspirepharm.com. Archived ve... |
| | | 09/01/06 | Inspire Announces Webcast of Presentation at Thomas Weisel Partners Annual Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--Sept. 1, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, will present at the Thomas Weisel
Partners Annual Healthcare Conference on Friday, September 8, 2006 at
10:20 am ET in Boston.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
... |
| | | 08/08/06 | Inspire Reports Second Quarter 2006 Financial Results; Second Quarter 2006 Revenue Increases 40% from Second Quarter 2005| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 8, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today reported financial results
for the second quarter ended June 30, 2006.
Total revenue for the second quarter of 2006 was $13.4 million
compared to $9.6 million for the second quarter of 2005. Co-promotion
revenue from net sales of Elestat(R) (epinastine HCl ophthalmic
solution) 0.05% was $9.4 million, an increase of 19% compared to $7.9
million recognized in the second quarter of 2005. D... |
| | | 08/07/06 | Inspire Terminates Phase 2 Clinical Trial for Platelet Aggregation Inhibitor| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 7, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
terminated its Phase 2 clinical trial of INS50589 Antiplatelet, based
on the unanimous recommendation of its independent Data Monitoring
Committee (DMC), following a planned interim safety analysis.
INS50589 is a selective and reversible inhibitor of the platelet
P2Y12 adenosine diphosphate receptor. The Phase 2 proof-of-concept
clinical trial was a randomized, dou... |
| | | 08/07/06 | Inspire Announces Vice President Appointments| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 7, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the hiring of two
new Vice Presidents, Bart J. Dunn as Vice President, Business
Development and Raymond W. Hines as Vice President, Associate General
Counsel.
"We are excited to welcome Bart and Ray, both highly experienced
and successful professionals, to our team," stated Christy L. Shaffer,
Ph.D., President and CEO of Inspire. "We are confident that their
expertise will se... |
| | | 08/04/06 | Inspire Announces Webcast of Presentation at Bank of America Specialty Pharmaceuticals Conference| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 4, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, and Michael R. Knowles, M.D.,
Professor of Medicine and Co-Director of the Adult Cystic Fibrosis
Program, University of North Carolina at Chapel Hill, will present at
the Bank of America Specialty Pharmaceuticals Conference on Friday,
August 11, 2006 at 10:30 am ET in Southampton, New York.
The topic of the presentation will b... |
| | | 07/27/06 | Inspire Initiates Phase 3 Clinical Trial of Denufosol Tetrasodium in Cystic Fibrosis Patients| DURHAM, N.C.--(BUSINESS WIRE)--July 27, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of
a Phase 3 clinical trial to evaluate its drug candidate, denufosol
tetrasodium Inhalation Solution, in patients with mild cystic fibrosis
(CF) lung disease.
The initial Phase 3 clinical trial, which will be referred to as
TIGER-1 (Transport of Ions to Generate Epithelial Rehydration), is
designed to include a 24-week efficacy treatment period, followed by a
... |
| | | 07/25/06 | Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2006 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--July 25, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to
report second quarter 2006 financial results on Tuesday, August 8,
2006 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on August 8, 2006 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877)
780-2276 and interna... |
| | | 07/05/06 | Inspire Announces Webcast of Presentation At C.E. Unterberg, Towbin Emerging Growth Conference| DURHAM, N.C.--(BUSINESS WIRE)--July 5, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R.
Staab, II, CFO and Treasurer, will present at the C.E. Unterberg,
Towbin Emerging Growth Conference on Wednesday, July 12, 2006 at 11:40
am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
ti... |
| | | 06/16/06 | Inspire to Present Data at 2006 European Cystic Fibrosis Conference| DURHAM, N.C., Jun 16, 2006 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced
today that Inspire scientists and collaborators will present
information at the 29th European Cystic Fibrosis (CF) Conference being
held June 15 - 18, 2006 in Copenhagen, Denmark.
A podium and poster presentation entitled "Denufosol Tetrasodium
Inhalation Solution: Results from Two Phase 2 Trials in CF Patients
with Mild to Moderate Lung Disease" will be presented by Lynn Smiley,
M.D., I... |
| | | 05/31/06 | Inspire Announces Webcast of Presentation at FTN Midwest Securities Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--May 31, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, and Thomas R. Staab, II, CFO and
Treasurer, will present at the FTN Midwest Securities Health Care
Conference on Wednesday, June 7, 2006 at 3:05 pm ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be a... |
| | | 05/31/06 | Inspire Announces Plans to Begin Phase 2 Testing of Intranasal Epinastine for Seasonal Allergic Rhinitis; Pre-Investigational New Drug Meeting Completed With FDA| DURHAM, N.C.--(BUSINESS WIRE)--May 31, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today plans to file an
Investigational New Drug (IND) application and begin Phase 2 clinical
testing of intranasal epinastine for the treatment of seasonal
allergic rhinitis, following the recent completion of a pre-IND
meeting with the U.S. Food and Drug Administration (FDA).
"We are pleased that the extensive data package on epinastine
allows us to progress into Phase 2 clinical t... |
| | | 05/09/06 | Inspire Reports First Quarter 2006 Financial Results; Co-Promotion Revenue for Q1 2006 More Than Double Q1 2005| DURHAM, N.C.--(BUSINESS WIRE)--May 9, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today reported financial results
for the first quarter ended March 31, 2006.
Total revenue for the first quarter of 2006 was $5.5 million
compared to $1.9 million for the first quarter of 2005. First quarter
2006 co-promotion revenue of $4.2 million reflected a 128% increase
over the first quarter of 2005. Total co-promotion revenue for the
first quarter of 2006 included $1.3 million from net ... |
| | | 04/28/06 | Inspire to Present Data at 2006 Association for Research in Vision and Ophthalmology Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--April 28, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists and collaborators will present information from six
abstracts at the 2006 Association for Research in Vision and
Ophthalmology (ARVO) Annual Meeting to be held April 30th - May 4th in
Ft. Lauderdale, Florida. All of the abstracts will be presented as
poster sessions.
The six posters to be presented include data on the study of dry
eye disease, cornea... |
| | | 04/26/06 | Inspire Announces Initiation of Phase 2 Clinical Trial of Platelet Aggregation Inhibitor| DURHAM, N.C.--(BUSINESS WIRE)--April 26, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today the initiation of
a Phase 2 clinical trial to evaluate Inspire's drug candidate,
INS50589 Antiplatelet, in patients undergoing coronary artery bypass
graft (CABG) surgery utilizing a cardiopulmonary bypass pump.
INS50589 is a selective and reversible inhibitor of the platelet
P2Y12 adenosine diphosphate receptor. The Phase 2 clinical trial is a
randomized, double-blind compar... |
| | | 04/25/06 | Inspire Announces Date for Conference Call and Webcast to Discuss First Quarter 2006 Financial Results| DURHAM, N.C., Apr 25, 2006 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (Nasdaq:ISPH) announced
today that it plans to report first quarter 2006 financial results on
Tuesday, May 9, 2006, before the market opens. Inspire's President and
CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R.
Staab, II, will host a conference call and live webcast on May 9,
2006, at 9:00 a.m. ET.
To access the conference call, U.S. participants may call
877-780-2276 and international partici... |
| | | 04/24/06 | Inspire Announces Webcasts of Presentations at Two Healthcare Conferences in Early May 2006| DURHAM, N.C.--(BUSINESS WIRE)--April 24, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that senior
executives from the Company will present at the Deutsche Bank
Securities 31st Annual Health Care Conference on Tuesday, May 2, 2006
at 9:45 a.m. ET in Boston, Massachusetts and at the Morgan Stanley
Global Healthcare Unplugged Conference on Thursday, May 4, 2006 at
10:30 a.m. ET in Miami, Florida.
Both presentations will be webcast on Inspire's web site at
www.in... |
| | | 04/19/06 | Inspire Announces Receipt of Milestone Payment from Japanese Dry Eye Partner| DURHAM, N.C., Apr 19, 2006 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced
today the receipt of a milestone payment from Santen Pharmaceutical
Co., Ltd. related to the development of diquafosol tetrasodium
ophthalmic solution for the therapeutic treatment of ocular surface
diseases, including dry eye, in Asia. The milestone payment of $1.25
million resulted from Santen's completion of its Phase 2 clinical
testing of diquafosol in the first quarter of 2006.
Chri... |
| | | 03/30/06 | Inspire to Present at Southeast Invest 2006 Conference| DURHAM, N.C.--(BUSINESS WIRE)--March 30, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, Chief Financial Officer and Treasurer, will present at the
SouthEast Invest 2006 Conference in Durham, North Carolina on
Thursday, April 6, 2006 at 8:35 a.m. ET.
The presentation will be webcast on Inspire's web site at
www.inspirepharm.com. An archived version of the webcast presentation
will also be available through this link for a limited time fo... |
| | | 03/28/06 | Inspire Announces Outcome of FDA Meeting on Dry Eye Program; Additional Information to be Provided to FDA as Next Step| DURHAM, N.C.--(BUSINESS WIRE)--March 28, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) met with the U.S. Food and Drug
Administration (FDA) on March 22, 2006 regarding the approvable letter
received from the FDA on December 1, 2005 for diquafosol tetrasodium
ophthalmic solution. The meeting with the FDA involved a broad
discussion of Inspire's dry eye clinical program for diquafosol.
Christy L. Shaffer, Ph.D., President and CEO of Inspire, stated,
"Based upon this meeting, we... |
| | | 03/14/06 | Inspire Announces Presentation of Data at American College of Cardiology Annual Meeting; Data on Inspire's Reversible P2Y12 Receptor Antagonist Presented in Two Poster Sessions| DURHAM, N.C.--(BUSINESS WIRE)--March 14, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that two
abstracts evaluating INS50589, Inspire's reversible P2Y12 receptor
antagonist targeted for use in acute cardiac care, were presented in
poster sessions at the American College of Cardiology's 55th Annual
Scientific Session, held March 11-14, 2006 at the Georgia World
Congress Center in Atlanta, Georgia.
The first poster, entitled, "Antiplatelet Treatment with P2Y12
... |
| | | 03/14/06 | Inspire to Webcast Investor Meeting on March 21, 2006| DURHAM, N.C.--(BUSINESS WIRE)--March 14, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today plans to webcast
its Research and Development Investor Meeting scheduled for Tuesday,
March 21, 2006 in New York City.
During this meeting, Inspire will review several R&D pipeline
programs. The meeting will include presentations by Inspire senior
executives and two key opinion leaders, who will address the unmet
medical needs in the disease areas of cystic fibrosis and nasa... |
| | | 02/28/06 | Inspire to Present at 26th Annual Cowen Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 28, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) will present at Cowen and Co.'s
26th Annual Health Care Conference at the Boston Marriott Copley Place
on Tuesday, March 7, 2006 at 1:30 p.m. ET.
The presentation will be webcast on Inspire's web site at
www.inspirepharm.com. An archived version of the webcast presentation
will also be available through this link for a limited time following
the conference.
About Inspire
Inspire is... |
| | | 02/28/06 | Inspire Reports Fourth Quarter and Full Year 2005 Financial Results; 2005 Revenue More than Double 2004| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 28, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today reported financial results
for the fourth quarter and year ended December 31, 2005.
Total revenue for the fourth quarter of 2005 was $5.2 million
compared to $3.7 million for the fourth quarter of 2004. Total revenue
for the year ended December 31, 2005 was $23.3 million as compared to
$11.1 million for the same period in 2004. Fourth quarter and full
year 2005 co-promotion revenues re... |
| | | 02/21/06 | Inspire Announces Development and License Agreement with Boehringer Ingelheim International for Intranasal Epinastine in the United States and Canada| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 21, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered
into a development and license agreement with Boehringer Ingelheim
International GmbH. Inspire will acquire certain exclusive rights to
develop and market an intranasal dosage form of epinastine in the
United States and Canada for the treatment or prevention of rhinitis.
Under this agreement, Inspire will have full responsibility for
the intranasal epinastine d... |
| | | 02/17/06 | Inspire Names Joseph M. Spagnardi Senior Vice President, General Counsel and Secretary| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 17, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that Joseph M.
Spagnardi, currently serving as the company's Vice President and
Deputy General Counsel, will be promoted to the executive officer
position of Senior Vice President, General Counsel and Secretary,
effective March 2, 2006. Mr. Spagnardi will be succeeding Barry G.
Pea, Executive Vice President of Corporate Development, General
Counsel and Secretary, who is resigning... |
| | | 02/14/06 | Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2005 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 14, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to
report fourth quarter and full year 2005 financial results on Tuesday,
February 28, 2006 before the market opens. Inspire's President and
CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R.
Staab, II, will host a conference call and live webcast on February
28, 2006 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877)
... |
| | | 02/09/06 | Inspire to Present at Deutsche Bank Small Cap Growth Conference| DURHAM, N.C., Feb 09, 2006 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced
today that Thomas R. Staab, II, Chief Financial Officer and Treasurer,
and Benjamin R. Yerxa, Ph.D., Chief, Scientific Operations and
Alliances, will present at the Deutsche Bank 2006 Small Cap Growth
Conference in Naples, Florida on Thursday, February 16, 2006 at 9:00
a.m. ET.
The presentation will be webcast on Inspire's web site at
www.inspirepharm.com. An archived version of the webc... |
| | | 01/30/06 | Denufosol Proceeding to Phase 3 Trials in Cystic Fibrosis| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 30, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced plans to initiate
a Phase 3 program to advance denufosol tetrasodium for the treatment
of cystic fibrosis (CF). This follows the successful completion of an
End-of-Phase 2 meeting with the U.S. Food and Drug Administration
(FDA).
"We are pleased to be moving this high-priority program into Phase
3 development," said Christy L. Shaffer, Ph.D., President and CEO of
Inspire. "A... |
| | | 01/20/06 | Inspire Discontinues Retinal Disease Drug Development Program| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 20, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
discontinued two Phase 2 pilot clinical trials of denufosol
tetrasodium intravitreal injection (INS37217 Ophthalmic) in patients
with macular edema and has no plans to conduct any further studies of
denufosol for the treatment of retinal disease.
The two pilot trials of denufosol were initiated in the second and
third quarters of 2005. The first trial was targeted... |
| | | 01/10/06 | Inspire Announces European Orphan Drug Designation for Denufosol Tetrasodium for Treatment of Cystic Fibrosis| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 10, 2006--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that denufosol
tetrasodium has been granted orphan drug designation for the treatment
of cystic fibrosis (CF) by the European Medicines Agency (EMEA).
According to the EMEA, orphan medicinal products are for
diagnosing, preventing or treating life-threatening or very serious
conditions that are rare and affect not more than five in 10,000
persons in the European Union (EU). An... |
| |
|
